Bayer Consumer Health's Future Undecided As Firm Kicks Off Strategic Review

Bayer's new CEO says nothing is off the table when it comes to assessing the future direction of the business. As part of a company-wide strategic review, he and his executive team will decide whether to break up or keep in place Bayer's three pillar structure, comprising Consumer Health, Pharmaceuticals and Crop Science.

hands holding up a paper cut-out showing arrows in different directions
• Source: Shutterstock

Bayer could be the next in line to spin-off its Consumer Health business. Kicking off a company-wide strategic review, new CEO Bill Anderson has promised investors that “nothing is off the table.”

Speaking as the German firm reported its Q2 results, Anderson – who took the helm on 1 June – said he was making a full assessment of Bayer’s strategic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By 

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.